FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q91015143> ?p ?o ?g. }

• Q91015143 description "2019 թվականի հունվարի 12-ին հրատարակված գիտական հոդված" @default.
• Q91015143 description "artículu científicu espublizáu en xineru de 2019" @default.
• Q91015143 description "im Januar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
• Q91015143 description "scientific article published on 12 January 2019" @default.
• Q91015143 description "wetenschappelijk artikel" @default.
• Q91015143 description "наукова стаття, опублікована 12 січня 2019" @default.
• Q91015143 name "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 name "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 type Item @default.
• Q91015143 label "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 label "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 prefLabel "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 prefLabel "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 P1433 Q91015143-36E10C95-1E46-4A26-8F9F-6AD827594A40 @default.
• Q91015143 P1476 Q91015143-16B147C7-063D-4839-865B-45EFC75D73AC @default.
• Q91015143 P2093 Q91015143-01422B94-1B31-4A8F-94A3-99A2083B1DA1 @default.
• Q91015143 P2093 Q91015143-0C3C3533-06C0-4DAF-9AB4-39DDCD39F489 @default.
• Q91015143 P2093 Q91015143-3CF39924-E7A9-4511-885F-4F9E2B17DFDD @default.
• Q91015143 P2093 Q91015143-4FA6A734-7DD3-4F25-9CAD-F7A45A0AA948 @default.
• Q91015143 P2093 Q91015143-6E12CAC4-1F8A-4380-9D82-3BE8CF5D207B @default.
• Q91015143 P2093 Q91015143-8E4C0FCD-0E69-44CC-A05D-C39E0E84AA32 @default.
• Q91015143 P2093 Q91015143-C861F348-F48F-4D2C-AAE3-7C631D5078C7 @default.
• Q91015143 P2093 Q91015143-D67C174B-8EB6-48E8-A641-AA4F591B6107 @default.
• Q91015143 P2093 Q91015143-EA44BEFB-3EC7-4246-8689-36E91E480CAC @default.
• Q91015143 P2093 Q91015143-ED9A54BB-E952-4618-8953-58F77B5B2F20 @default.
• Q91015143 P2860 Q91015143-065020C7-0047-4ED9-874E-91D4A7098AC5 @default.
• Q91015143 P2860 Q91015143-084E227C-C4DD-4E70-94F8-EA0DF009F7B0 @default.
• Q91015143 P2860 Q91015143-0F85F0B3-DB19-4FDE-8C05-C236F9B63521 @default.
• Q91015143 P2860 Q91015143-1581F4F2-9D33-439B-978E-547528AF3AFA @default.
• Q91015143 P2860 Q91015143-17AC021A-2C1B-46CF-BEDC-C86E93C2E757 @default.
• Q91015143 P2860 Q91015143-24ABC69B-0C1F-4F37-8572-1C750E00A73F @default.
• Q91015143 P2860 Q91015143-2F7ADB1A-4352-4BAE-8163-825DB2AFA96C @default.
• Q91015143 P2860 Q91015143-3381C96D-8BF7-4641-B8A6-9F14BB64ABFF @default.
• Q91015143 P2860 Q91015143-36FB5D14-BC4E-472E-A9E9-CD53B435FCD8 @default.
• Q91015143 P2860 Q91015143-371BFA6A-FF69-41DF-845D-858ED127B360 @default.
• Q91015143 P2860 Q91015143-3DC4CD1B-6C39-4BB9-9531-B3E4764F4271 @default.
• Q91015143 P2860 Q91015143-3F88270D-5B7E-456D-800E-9B68D14B69EC @default.
• Q91015143 P2860 Q91015143-45C851BA-2FD8-4582-9528-16D2F1893766 @default.
• Q91015143 P2860 Q91015143-4B74A169-1416-4C22-B405-ECC450445014 @default.
• Q91015143 P2860 Q91015143-55BC76F6-4328-4873-8213-CC54C4F7E291 @default.
• Q91015143 P2860 Q91015143-5A515384-F50F-489F-84DC-430B7BF9B7C8 @default.
• Q91015143 P2860 Q91015143-5AAD9721-C0F8-436C-A077-BB81E6DA8765 @default.
• Q91015143 P2860 Q91015143-631D1A7F-5331-4402-93BD-F71B4F742F89 @default.
• Q91015143 P2860 Q91015143-67D178A7-FF74-4384-9865-B8584A39923C @default.
• Q91015143 P2860 Q91015143-7823F3B6-6DDE-4E87-89CC-98048615BFD9 @default.
• Q91015143 P2860 Q91015143-7C5DF11A-A920-469A-AB06-259198A1420D @default.
• Q91015143 P2860 Q91015143-7D89FEB9-51C9-42D9-B732-30772E3984E4 @default.
• Q91015143 P2860 Q91015143-886C39DE-5244-42F0-AF2C-8B81B444DF5C @default.
• Q91015143 P2860 Q91015143-8FE627E6-32A5-43EC-949C-A9FCD2111568 @default.
• Q91015143 P2860 Q91015143-98816654-2578-4B1E-8301-8D9FC39B3B15 @default.
• Q91015143 P2860 Q91015143-9B0B09EE-2F43-4F5A-8CC6-75A7A65112C8 @default.
• Q91015143 P2860 Q91015143-9B53721D-1119-4F01-8C41-792E87035395 @default.
• Q91015143 P2860 Q91015143-9B83DADE-D95C-41CC-940A-C37A3EBA1ED6 @default.
• Q91015143 P2860 Q91015143-9C1F3E79-9C12-43F7-91B4-0810DCAA38CA @default.
• Q91015143 P2860 Q91015143-9C7641E5-3100-439B-9A89-62A6C2DD13EC @default.
• Q91015143 P2860 Q91015143-A972FCAF-D089-4DDA-8D93-5DE533E57D67 @default.
• Q91015143 P2860 Q91015143-ABE3B956-4EAB-404F-BB1E-4E3AB04439D6 @default.
• Q91015143 P2860 Q91015143-ADFD5F85-1842-4D42-84FA-BF8B43F41160 @default.
• Q91015143 P2860 Q91015143-B0D6AC26-456C-4F0F-8ECD-0DCA9ADFCB4C @default.
• Q91015143 P2860 Q91015143-B35C3772-F1E0-4667-A7E9-EB482B03D1CE @default.
• Q91015143 P2860 Q91015143-BE34D715-B8BA-4E97-A557-2900B4B67376 @default.
• Q91015143 P2860 Q91015143-C307A7FB-FFAA-44E4-9CE1-BE74EB5D7BB7 @default.
• Q91015143 P2860 Q91015143-C49E5E76-0340-4EC5-B3FF-DF8946B2226C @default.
• Q91015143 P2860 Q91015143-C593CD9A-5D75-42E6-BAD0-8531261AD5A5 @default.
• Q91015143 P2860 Q91015143-C829C2B2-5C4C-47C8-A9AF-E6E5C2CA2531 @default.
• Q91015143 P2860 Q91015143-CBCDBF7B-B4E0-4C29-92C5-095B83761571 @default.
• Q91015143 P2860 Q91015143-CDBE3180-6A0A-4BE2-91AA-B8EA01A3B9CC @default.
• Q91015143 P2860 Q91015143-D62D359F-64B7-4748-BC03-21F0F9B23424 @default.
• Q91015143 P2860 Q91015143-E05E0E5F-4CAE-4F44-BDB4-26CB81FFF331 @default.
• Q91015143 P2860 Q91015143-E19432D9-B0FA-4497-9748-AE5BDD748C90 @default.
• Q91015143 P2860 Q91015143-E2D0D48B-B17D-4F45-8DFB-A7C1169DC579 @default.
• Q91015143 P2860 Q91015143-E6067091-87A4-4737-AA9C-B1477F3B5DE3 @default.
• Q91015143 P2860 Q91015143-F1C8C60F-F37C-4105-845E-C8C791F0746C @default.
• Q91015143 P2860 Q91015143-F5B4C202-49F5-4855-BCBD-D6D42ECE96C1 @default.
• Q91015143 P2860 Q91015143-F78A5BF7-948D-46F7-B4B8-83E8E497C891 @default.
• Q91015143 P2860 Q91015143-FF80C782-C04D-47DF-B905-4BCA0A6F1BF2 @default.
• Q91015143 P304 Q91015143-C94889E7-CE30-4117-A741-4B09E02B7B0E @default.
• Q91015143 P31 Q91015143-15D7E7F8-4BA3-4021-B249-0CF26750A059 @default.
• Q91015143 P356 Q91015143-0DD30673-F9AD-4B56-9308-E060A7717AE8 @default.
• Q91015143 P433 Q91015143-5C5DF2CE-AFD2-4F58-8424-D530CF171479 @default.
• Q91015143 P478 Q91015143-3659A2B6-05F1-4082-97CA-188478F9EF46 @default.
• Q91015143 P50 Q91015143-7AE9DB90-0F40-42B4-9405-709A899DE2DC @default.
• Q91015143 P577 Q91015143-DD171820-F698-421F-9F1A-D18591CA2825 @default.
• Q91015143 P698 Q91015143-5AE87E52-973C-41B0-AEC5-1AB873E2A19C @default.
• Q91015143 P921 Q91015143-0BCC93F2-33ED-4D18-BB82-AEC473599E9B @default.
• Q91015143 P921 Q91015143-471009FB-02BE-4A72-AE61-B27D93282348 @default.
• Q91015143 P921 Q91015143-AF391FA2-1D3A-44A6-A6AB-2CCB3CA34825 @default.
• Q91015143 P921 Q91015143-E6FC8783-9025-483F-9F66-92CB333E3AB3 @default.
• Q91015143 P356 HED.25640 @default.
• Q91015143 P698 30636183 @default.
• Q91015143 P1433 Q13703062 @default.
• Q91015143 P1476 "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
• Q91015143 P2093 "Chang-Fang Chiu" @default.
• Q91015143 P2093 "Chang-Yao Chu" @default.
• Q91015143 P2093 "Chao-Jung Tsao" @default.
• Q91015143 P2093 "Chia-Jui Yen" @default.
• Q91015143 P2093 "Chih-Cheng Chen" @default.
• Q91015143 P2093 "Ching-Yun Hsieh" @default.
• Q91015143 P2093 "Hsiao-Hui Tsou" @default.
• Q91015143 P2093 "Jang-Yang Chang" @default.

• next